Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

SCRI Development Innovations

Status and phase

Terminated

Phase 2

Conditions

Breast Cancer

Treatments

Drug: Docetaxel

Drug: Epirubicin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193024

GIA 11168

378-ONC-0030-219

SCRI BRE 39

Details and patient eligibility

About

The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.

Full description

Upon determination of eligibility, all patients will receive:

Docetaxel + Epirubicin

Both drugs will be repeated at 21-day intervals

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Metastatic breast cancer confirmed by biopsy.
Received no previous chemotherapy for metastatic breast cancer.
Prior hormonal therapy is acceptable.
Measurable or evaluable disease.
Able to perform activities of daily living without considerable assistance
Adequate bone marrow, liver and kidney function
Must be able to understand the nature of this study and give written informed consent.

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Age < 18 years.
Cardiac ejection fraction < 45%.
Women who are pregnant or lactating.
Patients with meningeal metastases are ineligible.
Moderate peripheral neuropathy
History of hypersensitivity reaction to Taxotere
Males with metastatic breast cancer

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.